Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

This publication has 19 references indexed in Scilit:

• Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
  The Lancet, 2006
• Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia
  Obstetrics & Gynecology, 2006
• Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
  The Lancet Oncology, 2005
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
  The Lancet, 2004
• Evaluating Human Papillomavirus Vaccination Programs
  Emerging Infectious Diseases, 2004
• Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
  JNCI Journal of the National Cancer Institute, 2004
• Cervical Screening in the National Breast and Cervical Cancer Early Detection Program, 1995–2001
  Obstetrics & Gynecology, 2004
• Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
  JAMA, 2003
• Chapter 13: Primary Screening of Cervical Cancer With Human Papillomavirus Tests
  JNCI Monographs, 2003
• Accuracy of the Papanicolaou Test in Screening for and Follow-up of Cervical Cytologic Abnormalities
  Annals of Internal Medicine, 2000